Arbutus Biopharma Corporation
HealthcareNASDAQ:ABUS · NASDAQ Global Select
-$0.03 today
Vol 0.94M · Avg 1.78M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $23.7M |
| Short-term Investments | $71.5M |
| Receivables | $1.3M |
| Other Current | $180.5M |
| Total Current Assets | $277.0M |
| PP&E (Net) | $22.0K |
| Other Non-current | $131.0K |
| Total Non-current Assets | $153.0K |
| Total Assets | $277.2M |
Analysis
Selected assets total $277.2M for Latest. The largest visible component is Other Current at $180.5M, about 65.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.0M -50.4% | $36.3M +38.2% | $26.3M -14.6% | $30.8M -71.8% | $109.3M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $73.5M -14.9% | $86.3M -13.5% | $99.7M -14.1% | $116.1M +152.3% | $46.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.7M -27.5% | $2.4M +35.6% | $1.8M +31.4% | $1.4M +50.4% | $899.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.2M -45.8% | $2.3M -46.2% | $4.2M +47.8% | $2.9M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $94.5M -25.8% | $127.3M -3.6% | $132.0M -12.6% | $151.1M -5.9% | $160.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $32.0K -99.3% | $4.4M -28.5% | $6.1M -10.6% | $6.8M -15.6% | $8.1M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 -100.0% | $6.3M -83.2% | $37.4M +4.7% | $35.7M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $130.0K +282.4% | $34.0K | $0 -100.0% | $103.0K +68.8% | $61.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $162.0K -96.3% | $4.4M -64.5% | $12.4M -72.1% | $44.3M +1.0% | $43.8M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $94.6M -28.2% | $131.7M -8.8% | $144.4M -26.1% | $195.4M -4.4% | $204.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $1.2M -49.4% | $2.3M -28.1% | $3.2M -8.4% | $3.5M +10.9% | $3.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $547.0K | $0 | $0 -100.0% | $372.0K | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $7.6M -35.8% | $11.8M -28.3% | $16.5M | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $4.3M | $0 -100.0% | $3.7M -57.9% | $8.8M | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $6.0M -61.5% | $15.6M -30.5% | $22.5M -31.6% | $32.9M +192.8% | $11.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $3.4M | $0 -100.0% | $7.0M -32.9% | $10.4M -36.4% | $16.3M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 -100.0% | $2.9M | $0 -100.0% | $6.0M | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $8.4M -44.2% | $15.1M +98.1% | $7.6M +0.9% | $7.5M +42.1% | $5.3M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $12.0M -35.7% | $18.7M +17.8% | $15.9M -38.2% | $25.7M +7.9% | $23.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $18.0M -47.5% | $34.3M -10.5% | $38.4M -34.5% | $58.6M +67.1% | $35.0M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.4B +0.8% | $1.4B +4.5% | $1.3B +2.4% | $1.3B +2.5% | $1.3B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.4B -2.5% | -$1.3B -5.5% | -$1.3B -6.1% | -$1.2B -6.1% | -$1.1B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$48.1M +0.1% | -$48.1M +0.6% | -$48.4M +4.1% | -$50.5M -4.5% | -$48.3M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 +100.0% | -$1 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $76.6M -21.4% | $97.4M -8.2% | $106.0M -22.5% | $136.9M -19.2% | $169.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $4.2M +224.9% | $1.3M -85.2% | $8.7M -30.5% | $12.6M -33.6% | $18.9M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$13.8M +60.6% | -$35.0M -99.5% | -$17.6M +3.6% | -$18.2M +79.8% | -$90.4M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
GH Research PLC
NASDAQ:GHRS
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
ProKidney Corp.
NASDAQ:PROK
$242.99M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ABUS have?
Arbutus Biopharma Corporation (ABUS) reported $18.01M in cash and equivalents in fiscal 2025.
How much debt does ABUS carry?
Arbutus Biopharma Corporation (ABUS) reported $4.19M of total debt, with net debt of -$13,820,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.